Cargando…

Dual CTLA-4 and PD-L1 Blockade Inhibits Tumor Growth and Liver Metastasis in a Highly Aggressive Orthotopic Mouse Model of Colon Cancer()()

Immune checkpoint inhibitors have shown clinical benefit in several cancer entities including metastatic microsatellite instable colorectal carcinomas. However, for the majority of metastatic colorectal carcinomas the potential and limitations of immune checkpoint inhibition is not fully understood....

Descripción completa

Detalles Bibliográficos
Autores principales:	Fiegle, E, Doleschel, D, Koletnik, S, Rix, A, Weiskirchen, R, Borkham-Kamphorst, E, Kiessling, F, Lederle, W
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Neoplasia Press 2019
Materias:	Original article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6700499/ https://www.ncbi.nlm.nih.gov/pubmed/31412307 http://dx.doi.org/10.1016/j.neo.2019.07.006

Ejemplares similares

Regorafenib enhances anti-PD1 immunotherapy efficacy in murine colorectal cancers and their combination prevents tumor regrowth
por: Doleschel, Dennis, et al.
Publicado: (2021)

Nilotinib Enhances Tumor Angiogenesis and Counteracts VEGFR2 Blockade in an Orthotopic Breast Cancer Xenograft Model with Desmoplastic Response
por: Zafarnia, Sara, et al.
Publicado: (2017)

Molecular Ultrasound Imaging Depicts the Modulation of Tumor Angiogenesis by Acetylsalicylic Acid
por: Mueller-Diesing, Flurin, et al.
Publicado: (2023)

Expression and biological function of the cellular communication network factor 5 (CCN5) in primary liver cells
por: Borkham-Kamphorst, Erawan, et al.
Publicado: (2023)

Failure of annexin-based apoptosis imaging in the assessment of antiangiogenic therapy effects
por: Lederle, Wiltrud, et al.
Publicado: (2011)

Impact of prophylactic TNF blockade in the dual PD-1 and CTLA-4 immunotherapy efficacy and toxicity
por: Alvarez, Maite, et al.
Publicado: (2019)

Change of Apoptosis and Glucose Metabolism in Lung Cancer Xenografts during Cytotoxic and Anti-Angiogenic Therapy Assessed by Annexin V Based Optical Imaging and (18)F-FDG-PET/CT
por: Gross, Jasmin, et al.
Publicado: (2021)

Erythropoietin Improves the Accumulation and Therapeutic Effects of Carboplatin by Enhancing Tumor Vascularization and Perfusion
por: Doleschel, Dennis, et al.
Publicado: (2015)

CTLA-4 and PD-1 Pathway Blockade: Combinations in the Clinic
por: Callahan, Margaret K., et al.
Publicado: (2015)

Data on Lipocalin 2 and phosphatidylinositol 3-kinase signaling in a methionine- and choline-deficient model of non-alcoholic steatohepatitis
por: Asimakopoulou, Anastasia, et al.
Publicado: (2017)

Expression analysis of inflammasomes in experimental models of inflammatory and fibrotic liver disease
por: Boaru, Sorina Georgiana, et al.
Publicado: (2012)

Chronic mineral oil administration increases hepatic inflammation in wild type mice compared to lipocalin 2 null mice
por: Borkham-Kamphorst, Erawan, et al.
Publicado: (2021)

Chronic Carbon Tetrachloride Applications Induced Hepatocyte Apoptosis in Lipocalin 2 Null Mice through Endoplasmic Reticulum Stress and Unfolded Protein Response
por: Borkham-Kamphorst, Erawan, et al.
Publicado: (2020)

Non-invasive Imaging and Modeling of Liver Regeneration After Partial Hepatectomy
por: Zafarnia, Sara, et al.
Publicado: (2019)

Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis
por: Tag, Carmen G., et al.
Publicado: (2015)

Intradermal DNA vaccination combined with dual CTLA-4 and PD-1 blockade provides robust tumor immunity in murine melanoma
por: Kos, Spela, et al.
Publicado: (2019)

Clinical efficacy and biomarker analysis of dual PD-1/CTLA-4 blockade in recurrent/metastatic EBV-associated nasopharyngeal carcinoma
por: Lim, Darren Wan-Teck, et al.
Publicado: (2023)

N-Glycosylation of Lipocalin 2 Is Not Required for Secretion or Exosome Targeting
por: Borkham-Kamphorst, Erawan, et al.
Publicado: (2018)

Hybrid µCT-FMT imaging and image analysis
por: Gremse, Felix, et al.
Publicado: (2015)

A phase 1b study of dual PD-1 and CTLA-4 or KIR blockade in patients with relapsed/refractory lymphoid malignancies
por: Armand, Philippe, et al.
Publicado: (2020)

Pharmacological Intervention in Hepatic Stellate Cell Activation and Hepatic Fibrosis
por: Schon, Hans-Theo, et al.
Publicado: (2016)

Development of a Systematic Review Protocol and a Scoping Review of Ultrasound-Induced Immune Effects in Peripheral Tumors
por: Rix, Anne, et al.
Publicado: (2021)

Interleukin-21 combined with PD-1 or CTLA-4 blockade enhances antitumor immunity in mouse tumor models
por: Lewis, Katherine E., et al.
Publicado: (2017)

Antimesothelioma Immunotherapy by CTLA-4 Blockade Depends on Active PD1-Based TWIST1 Vaccination
por: Tan, Zhiwu, et al.
Publicado: (2020)

Synergistic Reversal of Intrahepatic HCV-Specific CD8 T Cell Exhaustion by Combined PD-1/CTLA-4 Blockade
por: Nakamoto, Nobuhiro, et al.
Publicado: (2009)

IMMU-13. Dual CTLA4/ PD-1 blockade improves survival for replication-repair deficient high-grade gliomas failing single agent PD-1 inhibition: An IRRDC study
por: Das, Anirban, et al.
Publicado: (2022)

Distinct immunological mechanisms of CTLA-4 and PD-1 blockade revealed by analyzing TCR usage in blood lymphocytes
por: Robert, Lidia, et al.
Publicado: (2014)

Emerging dynamics pathways of response and resistance to PD-1 and CTLA-4 blockade: tackling uncertainty by confronting complexity
por: Relecom, Allan, et al.
Publicado: (2021)

Small vessel vasculitis and dry gangrene secondary to combined CTLA-4 and PD-1 blockade in malignant mesothelioma
por: Kefas, Joanna, et al.
Publicado: (2022)

Reprogramming Intrahepatic Cholangiocarcinoma Immune Microenvironment by Chemotherapy and CTLA-4 Blockade Enhances Anti-PD1 Therapy
por: Chen, Jiang, et al.
Publicado: (2023)

The introduction of LAG-3 checkpoint blockade in melanoma: immunotherapy landscape beyond PD-1 and CTLA-4 inhibition
por: Kreidieh, Firas Y., et al.
Publicado: (2023)

CTLA-4 blockade: therapeutic potential in cancer treatments
por: Tarhini, Ahmad A, et al.
Publicado: (2010)

Anti-PD-1 checkpoint blockade monotherapy in the orthotopic GL261 glioma model: the devil is in the detail
por: Tritz, Zachariah P, et al.
Publicado: (2021)

Lipid-encapsulated siRNA for hepatocyte-directed treatment of advanced liver disease
por: Woitok, Marius Maximilian, et al.
Publicado: (2020)

Bio-degradable highly fluorescent conjugated polymer nanoparticles for bio-medical imaging applications
por: Repenko, Tatjana, et al.
Publicado: (2017)

Evolution of contrast agents for ultrasound imaging and ultrasound-mediated drug delivery
por: Paefgen, Vera, et al.
Publicado: (2015)

Dual IL-6 and CTLA-4 blockade regresses pancreatic tumors in a T cell– and CXCR3-dependent manner
por: Ware, Michael Brandon, et al.
Publicado: (2023)

Distinct Dynamics of Migratory Response to PD-1 and CTLA-4 Blockade Reveals New Mechanistic Insights for Potential T-Cell Reinvigoration following Immune Checkpoint Blockade
por: Safaeifard, Fateme, et al.
Publicado: (2022)

PD-1/CTLA-4 Blockade Leads to Expansion of CD8(+)PD-1(int) TILs and Results in Tumor Remission in Experimental Liver Cancer
por: Bufe, Sandra, et al.
Publicado: (2022)

Dual PD-1 and CTLA-4 Checkpoint Blockade Using Balstilimab and Zalifrelimab Combination as Second-Line Treatment for Advanced Cervical Cancer: An Open-Label Phase II Study
por: O'Malley, David M., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_go3cggo11qh9g9qghdkgug8c6f